LGND Q3 2019 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$25M-45.7% YoY

Gross Profit

$22M87.3% margin

Operating Income

-$5M-20.8% margin

Net Income

-$15M-61.5% margin

EPS (Diluted)

$-0.81

QoQ Revenue Growth

-0.7%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$697M

Stockholders' Equity

$851M

Cash & Equivalents

$1.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$25M	$46M	-45.7%
Gross Profit	$22M	$44M	-51.0%
Operating Income	-$5M	$23M	-122.1%
Net Income	-$15M	$67M	-122.6%